Compare BBCP & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBCP | SGHT |
|---|---|---|
| Founded | 1983 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.5M | 235.0M |
| IPO Year | 2017 | 2021 |
| Metric | BBCP | SGHT |
|---|---|---|
| Price | $7.30 | $4.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $8.25 | ★ $9.08 |
| AVG Volume (30 Days) | 98.0K | ★ 331.1K |
| Earning Date | 06-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $392,867,000.00 | $77,363,000.00 |
| Revenue This Year | $4.90 | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.56 | $3.11 |
| 52 Week High | $8.13 | $9.24 |
| Indicator | BBCP | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 56.02 |
| Support Level | $6.64 | $3.29 |
| Resistance Level | $7.76 | $5.46 |
| Average True Range (ATR) | 0.27 | 0.41 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 22.43 | 55.88 |
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.